Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Prepaid Assets (2016 - 2025)

Northwest Biotherapeutics' Prepaid Assets history spans 16 years, with the latest figure at $2.2 million for Q4 2025.

  • Quarterly results put Prepaid Assets at $2.2 million for Q4 2025, up 14.79% from a year ago — trailing twelve months through Dec 2025 was $2.2 million (up 14.79% YoY), and the annual figure for FY2025 was $2.2 million, up 14.79%.
  • Prepaid Assets for Q4 2025 was $2.2 million at Northwest Biotherapeutics, down from $2.3 million in the prior quarter.
  • In the past five years, Prepaid Assets ranged from a high of $5.7 million in Q1 2021 to a low of $1.7 million in Q3 2023.
  • The 5-year median for Prepaid Assets is $2.3 million (2022), against an average of $2.6 million.
  • Peak annual rise in Prepaid Assets hit 102.96% in 2021, while the deepest fall reached 61.63% in 2021.
  • Year by year, Prepaid Assets stood at $2.1 million in 2021, then rose by 15.98% to $2.5 million in 2022, then decreased by 18.74% to $2.0 million in 2023, then fell by 5.6% to $1.9 million in 2024, then rose by 14.79% to $2.2 million in 2025.
  • According to Business Quant data, Prepaid Assets over the past three periods came in at $2.2 million, $2.3 million, and $1.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.